Skip to main content
Open Access Publications from the University of California


UC San Francisco Previously Published Works bannerUCSF

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.

  • Author(s): Fuchs, Anke;
  • Gliwiński, Mateusz;
  • Grageda, Nathali;
  • Spiering, Rachel;
  • Abbas, Abul K;
  • Appel, Silke;
  • Bacchetta, Rosa;
  • Battaglia, Manuela;
  • Berglund, David;
  • Blazar, Bruce;
  • Bluestone, Jeffrey A;
  • Bornhäuser, Martin;
  • Ten Brinke, Anja;
  • Brusko, Todd M;
  • Cools, Nathalie;
  • Cuturi, Maria Cristina;
  • Geissler, Edward;
  • Giannoukakis, Nick;
  • Gołab, Karolina;
  • Hafler, David A;
  • van Ham, S Marieke;
  • Hester, Joanna;
  • Hippen, Keli;
  • Di Ianni, Mauro;
  • Ilic, Natasa;
  • Isaacs, John;
  • Issa, Fadi;
  • Iwaszkiewicz-Grześ, Dorota;
  • Jaeckel, Elmar;
  • Joosten, Irma;
  • Klatzmann, David;
  • Koenen, Hans;
  • van Kooten, Cees;
  • Korsgren, Olle;
  • Kretschmer, Karsten;
  • Levings, Megan;
  • Marek-Trzonkowska, Natalia Maria;
  • Martinez-Llordella, Marc;
  • Miljkovic, Djordje;
  • Mills, Kingston HG;
  • Miranda, Joana P;
  • Piccirillo, Ciriaco A;
  • Putnam, Amy L;
  • Ritter, Thomas;
  • Roncarolo, Maria Grazia;
  • Sakaguchi, Shimon;
  • Sánchez-Ramón, Silvia;
  • Sawitzki, Birgit;
  • Sofronic-Milosavljevic, Ljiljana;
  • Sykes, Megan;
  • Tang, Qizhi;
  • Vives-Pi, Marta;
  • Waldmann, Herman;
  • Witkowski, Piotr;
  • Wood, Kathryn J;
  • Gregori, Silvia;
  • Hilkens, Catharien MU;
  • Lombardi, Giovanna;
  • Lord, Phillip;
  • Martinez-Caceres, Eva M;
  • Trzonkowski, Piotr
  • et al.

Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View